

SUPPLEMENTARY MATERIAL

Durability of Response to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial

Melinda J. Gooderham, Giampiero Girolomoni, Julian O. Moore, Jonathan I. Silverberg, Robert Bissonnette, Seth Forman, Elena Peeva, Pinaki Biswas, Hernan Valdez, Gary Chan

Corresponding author:

Gary Chan

Pfizer Inc.

445 Eastern Point Road

Groton, CT 06340



gary.chan@pfizer.com

Supplementary Table 1. The list of participating Institutional Review Boards (IRBs) or Ethic Committees (ECs)


Study Site Number	IRB or EC
Australia	
1036	Melbourne Health Human Research Ethics Committee Royal Melbourne Hospital, Grattan Street Parkville, VIC 3050 Australia
1035, 1043, 1046, 1052, 1056, 1079, 1086	Bellberry Limited Human Research Ethics Committee 129 Glen Osmond Road Eastwood, SA 5063 Australia
Canada	
1037, 1040, 1071, 1090	Western Institutional Review Board 1019 39TH AVE SE, Ste 120 Puyallup, WA 98374-2115 USA
1038, 1039, 1045, 1047, 1072	Research Review Board Inc. 19 - 13085 Yonge Street, Suite 203 Richmond Hill, ON L4E 0K2 Canada
1070	The University of British Columbia Office of Research Ethics Clinical Research Ethics Board Room 210, 828 West 10th Avenue Vancouver, BC V5Z 1L8 Canada
1073	University of Manitoba Bannatyne Campus Research Ethics Boards Biomedical Research Ethics Board Ethics Boards Biomedical Research Ethics Board (BREB), 770 Bannatyne Avenue, Room P126 Winnipeg, MB R3E 0W3 Canada
Germany	
1031, 1033, 1034, 1041, 1055, 1074, 1077, 1085	Ethikkommission der Universität zu Lübeck Haus 2, Ratzeburger Allee 160 Lübeck, 23562 Germany
Hungary	
1080, 1082, 1083, 1084	Egeszsegugyi Tudomanyos Tanacs, Klinikai Farmakologiai Etikai Bizottsaga Arany Janos utca 6-8 Budapest, 1051 Hungary
United States	

<p>1001, 1002, 1003, 1004, 1005, 1006, 1008, 1009, 1010, 1012, 1013, 1014, 1015, 1018, 1019, 1021, 1023, 1024, 1027, 1028, 1029, 1030, 1049, 1050, 1058, 1059, 1060, 1062, 1063, 1064, 1066, 1076, 1078, 1091, 1092</p>	<p>Copernicus Group IRB One Triangle Dr, Suite 100 Durham, NC 27713 USA</p>
<p>1067</p>	<p>Human Subjects Protection Office (HSPO) & Institutional Review Board UConn Health 263 Farmington Ave Farmington, CT 06030-1511 USA</p>
<p>1069</p>	<p>Western Institutional Review Board 1019 39TH AVE SE, Ste 120 Puyallup, WA 98374-2115 USA</p>
<p>1075</p>	<p>IRB Human Research Protection Program 150 Munson St, 3rd Fl, PO Box 208317 New Haven, CT 06520-8327 USA</p>

Supplementary Fig. 1 Effect of abrocitinib on biomarkers during abrocitinib treatment and discontinuation. Median concentration of serum (a) high-sensitivity C-reactive protein, (b) interleukin-31, (c) eosinophil percentage, and (d) thymus and activation-regulated chemokine. *hs-CRP* high-sensitivity C-reactive protein, *IL-31* interleukin-31, *TARC* thymus and activation-regulated chemokine.



(c) Eosinophil %



(d) TARC

